• Explore /
  • Poster
  • / A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.

A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.

Abstract Video & Slides Poster

Authors

null

Gerald Steven Falchook

Sarah Cannon Research Institute at HealthONE, Denver, CO

Gerald Steven Falchook , Jason J. Luke , James F. Strauss , Xin Gao , Patricia LoRusso , PEI JYE VOON , Cong Li , Michael Shaw , Richard C. Gregory , Kristin Horn , John Gibbs , Neil Lineberry , Kate Stumpo , Karim Malek , Anthony J. Olszanski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT04420884

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS2670)

DOI

10.1200/JCO.2021.39.15_suppl.TPS2670

Abstract #

TPS2670

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Jennifer Robinson Diamond

First Author: Benjamin T. Cooper

First Author: Iwona A. Lugowska

First Author: David Shao Peng Tan